Log In Sign up
The largest database of trusted experimental protocols

Nedisertib

Manufactured by MedChemExpress
Visit Supplier

Nedisertib is a laboratory reagent used for research purposes. It is a small molecule inhibitor designed to target a specific protein or signaling pathway. The core function of Nedisertib is to enable researchers to investigate the role of this target in cellular processes or disease models, though its specific applications are not described here.

Automatically generated - may contain errors

Lab products found in correlation

Azd7648, by MedChemExpress (2 mentions) Mg132, by Merck Group (2 mentions) Ceralasertib, by MedChemExpress (2 mentions) Sn 38, by Selleck Chemicals (2 mentions) Adavosertib, by MedChemExpress (2 mentions) 5 fluorouracil, by Selleck Chemicals (2 mentions) Oxaliplatin, by Selleck Chemicals (2 mentions) Berzosertib, by MedChemExpress (2 mentions) Rabusertib, by MedChemExpress (2 mentions) Azd0156, by MedChemExpress (2 mentions) Olaparib, by Selleck Chemicals (2 mentions) Olaparib, by Apexbio (1 mentions) Veliparib abt 888, by Selleck Chemicals (1 mentions) Niraparib, by Selleck Chemicals (1 mentions) Rucaparib, by Selleck Chemicals (1 mentions) Cisplatin, by Apexbio (1 mentions) Carboplatin, by Apexbio (1 mentions) 5 fluorouracil, by Apexbio (1 mentions) Nms p118, by Selleck Chemicals (1 mentions) Cisplatin, by Adooq (1 mentions)

4 protocols using nedisertib

1

Comprehensive Synthetic Compound Library

Check if the same lab product or an alternative is used in the 5 most similar protocols
Olaparib (Catalog# A4154), cisplatin (Catalog# A8321), carboplatin (Catalog# A2171), and 5-fluorouracil (Catalog# A4071) were all purchased from APExBIO company. UPF 1096 (Catalog# S8038), NMS-P118(Catalog# S8363), stenoparib (E7449) (Catalog# S8419), niraparib (Catalog# S2741), rucaparib (Catalog# S4948), and veliparib (ABT-888) (Catalog# S1004) were all purchased from Selleckchem.
cisplatin (Catalog# A10221) was purchased from AdooQ Bioscience. ART-558(Catalog# HY-141520), DNA-PK inhibitors PIK-75 hydrochloride (Catalog# HY-13281), Nedisertib (Catalog# HY-101570) and AZD-7648 (Catalog# HY-111783), RAD51 Inhibitor B02 (Catalog# HY-101462), and Olaparib (for in vivo experiment: Catalog# HY-10162) were all purchased from MCE (MedChem Express). ART-812 was synthetized by Dr. Wayne Childers at Temple University School of Pharmacy. All compounds were dissolved, aliquoted, and stored following the manufacturer’s instructions.
Li H., Chatla S., Liu X., Vekariya U., Kim D., Walt M., Lian Z., Morton G., Feng Z., Yang D., Liu H., Reed K., Childers W., Yu X., Madzo J., Chitrala K.N., Skorski T, & Huang J. (2023). Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells. Research Square.
+ Open protocol
+ Expand
2

SSTR2-Expressing Cell Line Panel

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
H1299-7 cells, constitutively overexpressing SSTR2 (a gift from Buck Rogers, Mallinckrodt Institute, St Louis, Missouri), AR42J cells expressing high SSTR2 and SKNBE-2 expressing low levels of SSTR2, are as described in Cullinane et al19 (link). The identity of the H1299-7 and SKNBE-2 cell lines was confirmed through STR profiling (AGRF, Melbourne, Australia). Nedisertib and AZD-7648 were purchased from Med Chem Express. LuTate was produced using [DOTA0, Tyr3] octreotate and carrier-added [177Lu] Lutetium chloride (IDB, the Netherlands).
Waldeck K., Van Zuylekom J., Cullinane C., Gulati T., Simpson K.J., Tothill R.W., Blyth B, & Hicks R.J. (2023). A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177Lutetium-DOTA-octreotate radionuclide therapy. Theranostics, 13(14), 4745-4761.
+ Open protocol
+ Expand
3

Drug Combination Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
5-fluorouracil (5-FU; S1209), oxaliplatin (S1224), SN-38 (S4908), and olaparib (AZD2281, Ku-0059436, S1060) were purchased from Selleckchem. Berzosertib (ATRi; HY-13902), ceralasertib (ATRi; HY-19323), rabusertib [CHK1 inhibitor (CHKi); HY-14720], adavosertib [Wee1 inhibitor (Wee1i); HY-10993], AZD0156 [ATM inhibitor (ATMi); HY-100016], and nedisertib [DNA-PK inhibitor (DNA-PKi); HY-101570] were purchased from MedChemExpress, while MG-132 (474790) was purchased from Merck and hydroxyurea (HU; H8627) from Sigma.
Durinikova E., Reilly N.M., Buzo K., Mariella E., Chilà R., Lorenzato A., Dias J.M., Grasso G., Pisati F., Lamba S., Corti G., Degasperi A., Cancelliere C., Mauri G., Andrei P., Linnebacher M., Marsoni S., Siena S., Sartore-Bianchi A., Nik-Zainal S., Di Nicolantonio F., Bardelli A, & Arena S. (2022). Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. Clinical Cancer Research, 28(17), 3874-3889.
+ Open protocol
+ Expand
4

Drug Combination Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
5-fluorouracil (5-FU; S1209), oxaliplatin (S1224), SN-38 (S4908), and olaparib (AZD2281, Ku-0059436, S1060) were purchased from Selleckchem. Berzosertib (ATRi; HY-13902), ceralasertib (ATRi; HY-19323), rabusertib [CHK1 inhibitor (CHKi); HY-14720], adavosertib [Wee1 inhibitor (Wee1i); HY-10993], AZD0156 [ATM inhibitor (ATMi); HY-100016], and nedisertib [DNA-PK inhibitor (DNA-PKi); HY-101570] were purchased from MedChemExpress, while MG-132 (474790) was purchased from Merck and hydroxyurea (HU; H8627) from Sigma.
Durinikova E., Reilly N.M., Buzo K., Mariella E., Chilà R., Lorenzato A., Dias J.M., Grasso G., Pisati F., Lamba S., Corti G., Degasperi A., Cancelliere C., Mauri G., Andrei P., Linnebacher M., Marsoni S., Siena S., Sartore-Bianchi A., Nik-Zainal S., Di Nicolantonio F., Bardelli A, & Arena S. (2022). Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer. Clinical Cancer Research, 28(17), 3874-3889.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!